Generating Knowledge - Impacting Health
  • Home
  • test
  • Fellowship Alumni
  • About Us
    • Founding
    • Leadership
    • Partner Institutions
    • Research Staff
    • Research Clinics
    • Policies
    • Awards
    • Financial Statements
  • Scientific Publications
  • Media
    • Media Releases
    • News and Events
    • Online Media Coverage
    • In the Press
    • Galleries
    • Videos
    • Fact Sheets
    • Brochures and Posters
  • Newsletters
  • Careers
    • Careers
    • Education
    • Reward and Recognition Programme
  • Contact

Latest Scientific Publication

Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.

Perumal R, Abdelghani N, Naidu N, Yende-Zuma N, Dawood H, Naidoo K, Singh N, Padayatchi N. JAIDS 2018; 78(5):536-542.

15 August 2018

READ MORE

Covid-19 Weekly Updates

READ REPORTS

Latest Scientific Publication

Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.

Perumal R, Abdelghani N, Naidu N, Yende-Zuma N, Dawood H, Naidoo K, Singh N, Padayatchi N. JAIDS 2018; 78(5):536-542.

15 August 2018

READ MORE

Covid-19 Weekly Updates

READ REPORTS

CAPRISA NEWS

test

25 August 2021

Read more

VIEW MORE NEWS

CAPRISA
CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA

CAPRISA was formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Research and Policy; and is the South African Department of Science and Innovation and the National Research Foundation‘s designated Centre of Excellence in HIV Prevention

The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV, TB and SARS-CoV-2 pathogenesis, epidemiology, prevention, and treatment. CAPRISA conducts research in four main Scientific Programmes namely: HIV and Covid-19 pathogenesis and vaccines; HIV and TB treatment; HIV epidemiology and prevention; and SARS-CoV-2 epidemiology, prevention, and vaccines.

Research activities at CAPRISA are supported by eight support cores including, administration, statistics, data management, laboratory, community, pharmacy, bioethics, and information systems.

The fiduciary and policy oversight of CAPRISA is governed by the Board of Control with senior industry officials. The CAPRISA Scientific Advisory Board is chaired by Nobel Laureate, Professor Françoise Barré-Sinoussi, Emeritus Professor at the Institut Pasteur in Paris.

DOWNLOAD THE CAPRISA BROCHURE

CAPRISA
In The Media

test

25 August 2021

March for science

16 April 2018

Science Rocks

15 April 2018

MORE ARTICLES

Awards

Latest CAPRISA
Newsletter

31 August 2018

DOWNLOAD

ARCHIVES
SUBSCRIBE TO NEWSLETTER

Contact Us | Terms and Conditions | Privacy Policy |Legal | The CAPRISA name logo is a registered Trademark Copyright © 2025 Developed by Loud Crowd Media. All rights reserved

We use cookies to make your experience with us better. By continuing to use our website, you are agreeing to our use of cookies. To find out more see our privacy policy.

Close